Stephen Lyle, MD, PhD
Dr. Stephen Lyle is responsible for the oversight of ProMedDx-sponsored clinical study protocols and serves as our technical liaison.
In addition to his role at ProMedDx, Dr. Lyle is the Molecular Diagnostics Lab Director at KEW Group. Previously, he was a professor of pathology at the University of Massachusetts Medical Center, lab director of Predictive Biosciences, and medical director at Catalyst Oncology. Board-certified in anatomic pathology and in dermatopathology, Dr. Lyle is a graduate of The Pritzker School of Medicine/University of Chicago where he completed his Doctor of Medicine and Doctor of Philosophy in biochemistry and molecular biology.